Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2004
Business Overview: Aastrom is a late-stage development company focused on the ex vivo production of human cell products for cell therapy and regenerative medicine. Its core technology is the patented AastromReplicell System, which uses single-pass perfusion to manufacture patient-specific cells. The company's primary product candidates are Tissue Repair Cells (TRCs) for bone and vascular regeneration, and Cell Production Products (CPP) for dendritic cell vaccines.
Key Financial Metrics
| Metric | Fiscal Year 2004 | Fiscal Year 2003 | Fiscal Year 2002 |
|---|---|---|---|
| Total Revenues | $1,302,000 | $844,000 | $877,000 |
| Net Loss | $(10,488,000) | $(9,579,000) | $(7,939,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.14) | $(0.19) | $(0.19) |
| Cash, Cash Equivalents & Short-Term Investments | $16,926,000 | $10,512,000 | $9,605,000 |
| Working Capital | $17,274,000 | $11,273,000 | $10,597,000 |
| Total Assets | $18,166,000 | $12,155,000 | $11,553,000 |
| Accumulated Deficit | $(113,864,000) | $(103,376,000) | $(93,797,000) |
Revenue Composition (2004): Grants accounted for 90% of total revenue ($1,178,000), primarily from DARPA and NIH. Product sales and rentals were minimal at $49,000.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 54% to $1.302 million, driven almost entirely by a 127% increase in grant revenue ($1.178 million vs. $520,000 in 2003).
- Product Sales Decline: Product sales and rentals dropped significantly to $49,000 from $314,000 in 2003 due to extended internal evaluations by potential customers delaying sales.
- Expense Increases: Total costs and expenses rose to $11.96 million (up 13%). Selling, general, and administrative (SG&A) expenses increased to $5.39 million due to expanded EU marketing and capital raising costs. R&D expenses increased to $6.29 million to support clinical trials.
- Liquidity Improvement: Cash and short-term investments increased by $6.4 million to $16.9 million, resulting from net proceeds of $16.1 million from equity sales during the year.
- Inventory Write-downs: The provision for obsolete and excess inventory decreased to $253,000 from $748,000 in 2003, as the carrying value of older inventory had been written down to zero in the prior year.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- The company does not expect to generate positive cash flows from operations for at least the next several years.
- Management expects available cash and interest income to fund planned activities through the end of fiscal year 2005 (June 30, 2005).
- Future capital requirements will depend on clinical trial results and regulatory approvals. Additional funding will be required to commercialize products.
Material Risks and Contingencies:
- Nasdaq Delisting Risk: On July 28, 2004, the company received notice that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive days. A grace period was granted until January 24, 2005, to regain compliance.
- Regulatory Uncertainty: The FDA regulates the company's cell products as biologics requiring a Biologics License Application (BLA). New EU directives have shifted patient-derived cells to the medicinal products category, potentially delaying clinical trials in Europe.
- Third-Party Dependence: The company relies on third-party manufacturers (e.g., Astro Instrumentation, Moll Industries) for critical components and Amgen for cytokines. Supply interruptions could halt development.
- Patent Expiration: Key patents licensed from the University of Michigan begin expiring in 2008, with the first underlying patent expiring in 2012.
Unusual Items:
- SG&A expenses included non-cash charges of $53,000 for warrants issued for investor relations services and $372,000 for a performance-based stock option vesting.
Investor Verification Checklist
- Cash Runway: Verify if the $16.9 million cash balance is sufficient to fund operations through 2005 given the $10.5 million annual burn rate.
- Nasdaq Compliance: Monitor stock price performance to ensure compliance with the $1.00 minimum bid price requirement by January 24, 2005, to avoid delisting.
- Grant Sustainability: Assess the reliance on government grants (90% of revenue) and the risk of funding discontinuation.
- Clinical Trial Progress: Review enrollment and safety data for the Phase I/II bone grafting trials in the U.S. and EU.
- Supply Chain Security: Confirm the status of the supply agreement with Amgen for cytokines and the manufacturing capacity of third-party partners.